Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
|Slideshows|August 13, 2019
- Drug Topics August 2019
- Volume 163
- Issue 8
Six New Clinical Services
Author(s)Tzipora Lieder, RPh
Pharmacogenetic testing, contraceptives, and more!
Advertisement
Articles in this issue
about 7 years ago
Reaching a New Generation of Consumersabout 7 years ago
New Drug Review: Vraylar for Bipolar I Disorderabout 7 years ago
AI in the Pharmacyabout 7 years ago
Zolgensma: The $2.1 Million Drugabout 7 years ago
Physician Dispensing and the Opioid Crisisabout 7 years ago
Psychotropics for Childrenabout 7 years ago
Improving the Customer Experienceabout 7 years ago
Birth Control Services Help Attract and Keep Patientsabout 7 years ago
Prevalence and Prevention of Sexual Harassment in the Pharmacyabout 7 years ago
Opinion: Clinician Burnout is Everyone's ProblemAdvertisement
Related to this article
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
Advertisement
Advertisement
Trending on Drug Topics
1
Nicotine Pouches Create Opportunity for Pharmacist Counseling
2
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Worth a Shot: How ACIP Changes Might Impact Vaccine Access, Coverage
5